#USA #Singapore #ALR Technologies #GluCurve Pet #CGM Medical

ALR Technologies Hits Milestone with CGM Manufacturing Agreement

ALR Technologies SG Ltd. (referred to as ALRT), a key player in diabetes management, has successfully finalized a manufacturing agreement with CGM Medical Technology Shen Zhen Ltd. This partnership is pivotal for the production of the Continuous Glucose Monitor (CGM) hardware, designed specifically for the innovative GluCurve Pet CGM.

The partnership grants ALRT exclusive global distribution rights for the CGM Medical's CGM hardware tailored for animal health, marking a major stride in the sector. The first shipment of these devices is expected in the third quarter of 2025, signaling a critical development phase for the company.

According to ALRT's Chairman and CEO, Mr. Sidney Chan, this endeavor represents more than just a production agreement; it outlines a vision of growth and integration in the diabetic market. “We have collaborated closely with CGM Medical to create a manufacturing line capable of producing CGM units at scale, crucial for the GluCurve Pet CGM project,” he stated. As production ramps up, ALRT plans to take a further step by establishing a joint venture with CGM Medical to build a fully automated manufacturing facility in Singapore, which is aimed at enhancing efficiency and reducing costs.

This manufacturing agreement is the cornerstone of ALRT's long-term strategy to solidify its role within the diabetes care market. It showcases the company's commitment to catering not only to human health but also to the health of pets, with products designed to optimize diabetic treatments for animals. The company is currently pursuing multiple initiatives in human healthcare, backed by interest from investors and commercial entities.

The Definitive Manufacturing Agreement does include certain stipulations, particularly concerning the performance of the CGM hardware meeting ALRT's stringent specifications.

About CGM Medical Technology Shen Zhen Ltd.

CGM Medical is noted for its innovative approaches in the medical device sector, focusing on continuous glucose monitoring technology. With a strong emphasis on affordability and accuracy, the company aims to enhance the quality of life for diabetic patients through its products. The management and design teams comprise seasoned professionals with substantial experience in glucose monitoring and comprehensive knowledge in automation, life sciences, and secure technology application.

About ALR Technologies SG Ltd.

ALR Technologies has earned a reputation for streamlining diabetes management. Its flagship offering is the ALRT Diabetes Solution, which features an FDA-compliant system for data management sourced directly from blood glucose meters. The platform also includes algorithms to predict A1C levels, further aiding healthcare providers in optimizing diabetes treatment plans. In its efforts to expand its outreach, ALRT's animal health division has created the GluCurve Pet CGM. This product is particularly beneficial for veterinarians, enabling them to improve insulin treatment assessment for companion animals.

For additional information on ALR Technologies and the GluCurve Pet CGM, visit www.alrt.com in the USA, or www.GluCurve.ca in Canada.

Investor Contact: For further inquiries related to investments, please reach out to ALRT’s investor relations at [email protected] | USA: +1 804 554 3500 | Singapore: +65 3129 2924.

Notice

This article may contain forward-looking statements, which are subject to risks and uncertainties. Actual results can greatly differ from those anticipated. ALRT disclaims any obligation to update or revise such statements unless required by law.